Clinical Trials Directory

Trials / Completed

CompletedNCT00051220

Treatment for Specific Phobias in Children

One-Session Treatment for Specific Phobias in Children

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
150 (actual)
Sponsor
Virginia Polytechnic Institute and State University · Academic / Other
Sex
All
Age
7 Years – 16 Years
Healthy volunteers
Not accepted

Summary

This study will compare the effectiveness of three treatments in reducing symptoms of phobia in children and adolescents.

Detailed description

Children with specific phobias may experience academic, social, and personal distress, as well as interference in day-to-day activities. One-Session Treatment has been found a rapid and effective treatment for adults with phobic disorders. However, its utility in the treatment of childhood phobia has not been examined. Participants are randomly assigned to 1 of 3 groups: a one-session treatment group, an education/support group, and a waitlist control group. The one-session treatment group is directly exposed to a phobia object or situation during a 3-hour treatment session. In the education/support group, children are given information about fear and phobias and are taught how to deal with them through workbook activities. Children who participate in the one-session treatment group or the education/support group are assessed 1 week post-treatment and again after 6 months. Participants with improved symptoms have a 1-year follow-up. Participants with phobias that persist at 6 months are encouraged to participate in alternative treatment. Waitlist control participants are assessed pre-treatment and 1 month post-treatment. Those who continue to have phobias at the 1-month assessment are randomly assigned to 1 of the 2 active treatments.

Conditions

Interventions

TypeNameDescription
BEHAVIORALOne-Session Treatment for Specific Phobias

Timeline

Start date
2001-10-01
Primary completion
2006-09-01
Completion
2006-09-01
First posted
2003-01-08
Last updated
2013-06-07

Locations

2 sites across 2 countries: United States, Sweden

Source: ClinicalTrials.gov record NCT00051220. Inclusion in this directory is not an endorsement.